EXPERT REACTION: US buys almost all global stock of COVID-19 drug remdesivir
Opinion piece/editorial: This work is based on the opinions of the author(s)/institution.
The US administration has bought almost all stock of the drug remdesivir for the next three months. The drug, produced by American pharmaceutical company Gilead, is one of only two drugs so far shown to help in the treatment of COVID-19. The Trump administration recently announced it has now bought more than 500,000 doses, which is all of Gilead's production for July and 90 per cent of August and September, leaving little for the rest of the world. Australian experts respond.
Organisation/s: Australian Science Media Centre, The University of Sydney, The University of Queensland, Australian Catholic University, The University of Melbourne, La Trobe University
Attachments:
Note: Not all attachments are visible to the general public
News for:
Australia
NSW
VIC
QLD
Media contact details for this story are only visible to registered journalists.
Expert Reaction
These comments have been collated by the Science Media Centre to provide a variety of expert perspectives on this issue. Feel free to use these quotes in your stories. Views expressed are the personal opinions of the experts named. They do not represent the views of the SMC or any other organisation unless specifically stated.
Dr Deborah Gleeson is a Senior Lecturer in the School of Psychology and Public Health at La Trobe University whose main research area is trade policy and access to pharmaceuticals
Associate Professor Barbara Mintzes is from the Charles Perkins Centre and Sydney Pharmacy School at the University of Sydney specialising in the study of pharmaceutical policy